Therapeutic area
Cardiovascular & Metabolic
Cardiometabolic conditions, heart failure, atherosclerotic vascular disease, diabetes, obesity, and endocrine disorders.
Core & active disease programs
Atherosclerotic Cardiovascular Disease
$381.0B attributable cost
$22.7B$ drug spend
143 assets · 1 indication
Hypertension
$347.4B+ attributable cost
$34.6B$+ drug spend
72 assets · 3 indications
Type 2 Diabetes
$324.6B attributable cost
$126.1B$ drug spend
131 assets · 1 indication
Obesity
$199.1B attributable cost
$10.6B$ drug spend
120 assets · 1 indication
Heart Failure
$27.7B+ attributable cost
$9.1B$+ drug spend
77 assets · 5 indications
Provisional & emerging programs (19)Early clinical pipeline & single-asset indications
Type 1 Diabetes
Familial Chylomicronemia Syndrome
Severe Hypertriglyceridemia
Cushing's Syndrome
Growth Hormone Deficiency
Homozygous Familial Hypercholesterolemia
Hypertrophic Cardiomyopathy
Cardiovascular Disease / Dyslipidemia
Congenital Adrenal Hyperplasia
Diabetes / Hypoglycemia
Hyperinsulinemic Hypoglycemia
Hypoparathyroidism
Hypoplastic Left Heart Syndrome
Hypothalamic Obesity
Male Hypogonadism
Mixed Hyperlipidemia
Peripheral Artery Disease
Vascular Trauma
Venous Thromboembolism